Update on Patent Ruling on ViiV Healthcare's EPZICOM® and TRIZIVIR®

GSK and ViiV Healthcare confirmed today that the US District Court for the District of Delaware upheld the validity of a patent covering the double combination of lamivudine and abacavir (Epzicom®) and the triple combination of lamivudine, abacavir and zidovudine (Trizivir®).
Source: GSK news - Category: Pharmaceuticals Source Type: news